Addex Therapeutics (ADXN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ADXN · Stock Price

USD 7.01+1.35 (+23.85%)

Market Cap: $8.4M

Historical price data

Market Cap: $8.4MPipeline: 8 drugs (2 Phase 3)Founded: 2002HQ: Geneva, Switzerland

Sector Ranking#350 in Small Molecule Drugs #89 in Neuroscience & CNS

Overview

Addex Therapeutics is a clinical-stage biotech focused on developing a new class of oral drugs—allosteric modulators—for neurological disorders. Its core achievement is building a robust pipeline of eight candidates, with lead programs in Phase 2/3 for Parkinson's disease dyskinesia (dipraglurant) and Phase 2 for epilepsy (ADX71149, partnered with Janssen). The company's strategy centers on advancing its proprietary GPCR modulation platform to create safer, more selective therapeutics, while pursuing strategic partnerships and funding to de-risk development and drive value.

NeurologyPsychiatry

Technology Platform

Proprietary platform for discovering oral small molecule allosteric modulators of G-protein coupled receptors (GPCRs), enabling fine-tuned modulation of neurological targets with potential for improved selectivity and safety.

Pipeline

8

8 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Dipraglurant	Parkinson Disease	Phase 2/3
Dipraglurant + Placebo	Parkinson Disease	Phase 2/3
ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo	Gastroesophageal Reflux	Phase 2
ADX10059 + ADX10059 Matching Placebo	Gastroesophageal Reflux	Phase 2
ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo	Migraine	Phase 2

Funding History

3

Total raised:$88M

PIPE$8MUndisclosedApr 15, 2020

IPO$60MUndisclosedJun 15, 2007

Series A$20MNovartis Venture FundMay 15, 2002

Opportunities

Lead program dipraglurant addresses a large, underserved market in Parkinson's disease dyskinesia with pivotal trial data as a near-term catalyst.

The validated partnership with Janssen provides non-dilutive funding and de-risks the epilepsy program.

The broad preclinical pipeline and spin-out activity demonstrate platform productivity for creating future value.

Risk Factors

High clinical failure risk inherent in drug development, particularly for novel mechanisms in neurology.

The company is pre-revenue and reliant on dilutive equity financing, with a low market cap indicating fragile financials.

Intense competition in target indications and potential commercialization challenges for a small biotech.

Competitive Landscape

Faces competition from approved and late-stage drugs in Parkinson's dyskinesia and a crowded epilepsy market. Its differentiation lies in pioneering allosteric modulation of specific GPCR targets (mGluR, GABAB). Competes with other biotechs focused on GPCR neurology platforms, but maintains a niche expertise in glutamate and GABA receptor modulation.